se of Amalaki seed paste in leucorrhea

Phase 2

• Conditions: Health Condition 1: N888- Other specified noninflammatory disorders of cervix uteri

• Registration Number: CTRI/2023/02/049567
• Lead Sponsor: DR. PADMAJA KALE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Females under reproductive age group of 18-45 years.

2. Female Patients with excessive amount of watery or mucoid vaginal white discharge.

3. Non purulent and non- offensive vaginal discharge.

4. Patients with chronic Pelvic Inflammatory Disease.

Exclusion Criteria

1. Pregnant women.

2. Positive history of Venereal diseases.

3. Patient having systemic disease like severe Anemia and Diabetes Mellitus.

4. Infective Vaginal discharges like Bacterial Vaginosis and VulvoVaginal candidiasis.

5. Rectovaginal fistula and Vesicovaginal fistula.

6. Known case of Malignant conditions of female reproductive system.

7. Uterine prolapse and acquired retroverted uterus.

8. Cervical lesion like chronic Cervicitis, Cervical ectropion and mucous polyp.

9. Vaginal discharge occurring due to Intrauterine contraceptive device (IUCDs)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To Assess the effect of oral consumption of Amalaki beej kalka with Madhu and Sharkara in <br/ ><br>management of Shweta pradara.Timepoint: Amalaki beeja kalka will be administered orally <br/ ><br>Schedule - once a day <br/ ><br>Duration -3 days <br/ ><br>Follow up - Follow up will be taken for two consecutive weeks and final follow up <br/ ><br> will be taken after 15 days.

Secondary Outcome Measures

Name	Time	Method
To Assess the effect of oral consumption of Amalaki beej kalka with Madhu and Sharkara in <br/ ><br>management of Shweta pradara.Timepoint: Amalaki beeja kalka will be administered orally <br/ ><br>Schedule - once a day <br/ ><br>Duration -3 days <br/ ><br>Follow up - Follow up will be taken for two consecutive weeks and final follow up <br/ ><br> will be taken after 15 days.